Pharmaceutical drug testing is the meticulous exploration of a compound's safety, efficacy, and potential side effects, marking a pivotal phase in the journey from discovery to market. This intricate process unfolds in a series of carefully designed trials, each serving a distinct purpose in unravelling the compound's impact on the human body. The journey begins with preclinical testing, where researchers delve into the compound's behaviour in the laboratory and animal models. This phase unveils insights into safety profiles, potential dosage ranges, and initial efficacy.
Upon successful preclinical evaluations, the compound progresses to clinical trials, a multi-phase endeavour involving human subjects. Phase 1 focuses on safety and dosage, Phase 2 delves into efficacy, and Phase 3 expands to larger populations, further validating the drug's effectiveness and monitoring for rare side effects. Regulatory bodies meticulously review the accumulated data, assessing the compound's risk-benefit profile before granting approval for market release. Post-marketing surveillance continues the scrutiny, ensuring ongoing safety and efficacy monitoring.
The evolution of pharmaceutical drug testing mirrors a meticulous orchestration of scientific inquiry, ethical considerations, and regulatory diligence. Each trial, from petri dish to patient, contributes to the collective endeavour of bringing safe and effective medications to those in need.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico